Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
Aged
Bone Density
Bone Density Conservation Agents
/ administration & dosage
Denosumab
/ administration & dosage
Diphosphonates
/ administration & dosage
Drug Administration Schedule
Female
Femur Neck
/ drug effects
Humans
Lumbar Vertebrae
/ drug effects
Middle Aged
Osteoporosis, Postmenopausal
/ drug therapy
Retrospective Studies
Teriparatide
/ administration & dosage
Bisphosphonate
denosumab
discontinuation
follow-on treatment
postmenopausal osteoporosis
Journal
Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
16
5
2020
medline:
15
5
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) ( Changes in LS BMD at 1.5 years after final DMAb administration were -2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL ( These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
Identifiants
pubmed: 32412351
doi: 10.1080/14397595.2020.1769895
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Teriparatide
10T9CSU89I
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM